DGAP-Adhoc: Limes Schlosskliniken AG: Positive Business Results in the First Half Year 2021
DGAP-Ad-hoc: Limes Schlosskliniken AG / Key word(s): Half Year Results/Development of Sales
Limes Schlosskliniken AG: Positive Business Results in the First Half Year 2021
01-Sep-2021 / 14:40 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP-Adhoc: Limes Schlosskliniken AG:
Positive business development in the first half year 2021
Key word: Half-Year Report 2021
- Total revenue EUR 8,2 million (p.y. EUR 4,6 million) +78,5 %
- Patient days 15.525 (p.y. 9.721) + 59,7 %
- Gross earnings (EBITDA) +2.278 kEUR (p.y. +15 kEUR)
- EBITDA-Margin 27,9 % (p.y. 0,3 %)
- Operating result (EBIT) + 1.675 kEUR (p.y. -509 kEUR)
- Result for shareholders of the parent company + 1.552 kEUR (p.y. -645 kEUR)
- Earning per share EUR + 5,29 (p.y. EUR -2,20)
- Positive business development expected to continue in second half year, good financial resources
Köln, September 01, 2021: The LIMES Schlosskliniken Group registered a very positive business performance in the first six months. Both clinics contributed to this result through good occupancy rates. Due to the positive patient response, we were able to significantly increase our occupancy rate.
Despite the difficult conditions caused by Covid-19 the clinic Mecklenburgische Schweiz was again able to expand revenue by +11% to a total of EUR 5 million in the first half of 2021. We expect the positive trend to continue in the second half of the year.
Our new clinic in Bad Brückenau already achieved revenue of EUR 3.2 million in the first half of the year. Occupancy rate is developing according to plan.
The start-up of the third LIMES Schlossklinik Bergisches Land located near Cologne is currently being prepared. The aim is to start clinic operations in the second quarter of 2022. We have approved the architectural designs for the construction of a fourth clinic.
The detailed Half-Year Report of LIMES Schlosskliniken Group will be published on 20.09.2021.
Short company profile: The LIMES Schlosskliniken Group operates high-quality private clinics for stress-related illnesses, mental and emotional disorders, such as depression, affective disorders and acute burnout conditions. The range of services is aimed at private patients, those entitled to state aid and self-payers. The LIMES Schlosskliniken Group stands for the special approach of a relationship-oriented medicine in the treatment of people with mental illnesses. In addition to top medical quality, patients are offered a unique, protected and healing environment in which they can recover holistically. Further information is available at www.limes-schlosskliniken.de.
Your contact person:
Limes Schlosskliniken AG, Petra Kaes, Investor Relations
Kaiser-Wilhelm-Ring 26, 50672 Köln
Tel.: 02203 / 29014-202, [email protected], www.limes-schlosskliniken.de
Language: English
Company: Limes Schlosskliniken AG
Kaiser-Wilhelm-Ring 26
50672 Köln
Germany
Tele.: 49 2203 29014-202
Fax: 49 2203 29014-201
Email: [email protected]
Internet: www.limes-schlosskliniken.de
ISIN: DE000A0JDBC7
WKN: AOJDBC
Stock exchange Düsseldorf Freiverkehr, Primärmarkt, XETRA
End of the message
01-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Limes Schlosskliniken AG |
|
Kaiser-Wilhelm-Ring 26 |
|
50672 Köln |
|
Germany |
ISIN: |
DE000A0JDBC7 |
WKN: |
A0JDBC |
Listed: |
Regulated Unofficial Market in Dusseldorf |
EQS News ID: |
1230467 |
|
End of Announcement |
DGAP News Service |
1230467 01-Sep-2021 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
6,54 |
7,43 |
8,18 |
11,02 |
23,44 |
28,81 |
37,17 |
EBITDA1,2 |
-0,49 |
-0,13 |
0,26 |
0,84 |
6,02 |
8,65 |
7,67 |
EBITDA-Marge3 |
-7,49 |
-1,75 |
3,18 |
7,62 |
25,68 |
30,02 |
|
EBIT1,4 |
-0,72 |
-0,93 |
-0,54 |
-0,43 |
4,53 |
6,00 |
5,03 |
EBIT-Marge5 |
-11,01 |
-12,52 |
-6,60 |
-3,90 |
19,33 |
20,83 |
13,53 |
Jahresüberschuss1 |
-1,25 |
-1,46 |
-0,83 |
-0,69 |
4,11 |
4,86 |
3,91 |
Netto-Marge6 |
-19,11 |
-19,65 |
-10,15 |
-6,26 |
17,53 |
16,87 |
10,52 |
Cashflow1,7 |
1,02 |
-0,66 |
0,17 |
0,76 |
4,77 |
8,04 |
6,29 |
Ergebnis je Aktie8 |
-4,95 |
-5,78 |
-2,81 |
-2,37 |
13,45 |
14,34 |
11,58 |
Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. ![](/wp-content/uploads/assets/icon/pdf_24x24.png)
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: B-S-H Collegen
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Limes Schlosskliniken |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A0JDBC |
378,000 |
Kaufen |
110,83 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
22,37 |
22,24 |
1,01 |
80,51 |
KBV |
KCV |
KUV |
EV/EBITDA |
7,33 |
17,61 |
2,98 |
14,65 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,00 |
0,00 |
0,00 |
10.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
|
03.09.2024 |
|
13.05.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
4,01% |
18,92% |
33,10% |
3,85% |
|
|